Bendamustin Hydrochloride in Patients With Soft Tissue Sarcoma (STS)

Multicenter Phase II Study With Bendamustin for Patients With Refractory Soft Tissue Sarcoma

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00204620

Enrollment

Registered

2005-09-20

Start date

2002-03-31

Completion date

2006-12-31

Last updated

2007-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcoma, Soft Tissue

Brief summary

The aims of this trial are to evaluate the efficacy of bendamustin in patients with metastatic soft tissue sarcoma who have progressed after or during an anthracycline-baesd chemotherapy and to assess the treatment of toxicity.

Interventions

DRUGBendamustin

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Histologically confirmed metastatic or non-resectable soft tissue sarcoma * Evidence of progression or relapse after an anthracycline-based and/ or ifosfamide-based chemotherapy * At least 1 bidimensionally measurable tumor lesion according to RECIST criteria * No previous radiation therapy on the only measurable lesion * Willingness to receive regular follow-up * Life expectancy more than 3 months * ECOG status \>= 2 * Patients aged 18 years and beyond * leucocytes \> 2500/µl, thrombocytes \> 75000/µl) * Serum creatine \< 1,5 times the upper limit of normal value, GFR \> 60/ml * Written patient informed consent * Ability to give informed consent

Exclusion criteria

* Previous or concurrent radiation of the index lesion (radiation of single lesion is allowed if not the index lesion) * Insufficient liver function (bilirubin \> 1.5 the upper limit of normal, prolongation of PT and aPTT \> 1.5 the upper limit of normal; ASAT and ALAT \> 3 the upper limit of normal (patients with liver metastases ASAT and ALAT \> 5 the upper limit of normal) * Active infection * Prior therapy with Bendamustin hydrochloride * Prior malignancies (other than adequately treated carcinoma in situ (CIS) of the cervix, bladder urothelium, basal cell carcinoma or adenoma of the colon including pTIS,pTIN), unless treated with curative intent and without evidence of disease \> 5 years * Symptomatic cardio- and/or cerebrovascular disease (NYHA-Scale III°) * Interval since last chemotherapy \< 4 weeks * Evidence of CNS-metastases * Evidence of pregnancy or lactation * Woman of child-bearing potential without reliable methods of birth control

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026